<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00652795</url>
  </required_header>
  <id_info>
    <org_study_id>40074</org_study_id>
    <nct_id>NCT00652795</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study Doxycycline Tablets and Monodox Capsules Under Fasting Conditions</brief_title>
  <official_title>Randomized, 2-Way Crossover, Bioequivalence Study of Doxycycline 150 mg Tablet and Monodox 50 mg Capsule Administered as 1 x 150 mg Tablet or 3 x 50 mg Capsules in Healthy Subjects Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Par Pharmaceutical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Anapharm</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Par Pharmaceutical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the rate and extent of absorption of doxycycline tablet (Par) versus doxycycline&#xD;
      capsule (Monodox)(Oclassen).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare the rate and extent of absorption of doxycycline 150 mg tablet (test) versus&#xD;
      Monodox 50 mg capsule (reference) administered as 1 x 50 mg tablet or 3 x 50 mg capsules&#xD;
      under fasting conditions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">September 2004</completion_date>
  <primary_completion_date type="Actual">September 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate and extent of absorption</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>To Determine Bioequivalence Under Fasting Conditions</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received the Par product (Doxycycline Monohydrate) under fasting conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received the Oclassen's product (Monodox) Capsules under fasting conditions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline Monohydrate</intervention_name>
    <description>Tablets, 150 mg, single-dose</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Monodox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Monodox</intervention_name>
    <description>Capsules 50 mg (3 x 50 mg dose), single-dose</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Doxycycline Monohydrate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or non-childbearing potential female, smoker or non-smokers&#xD;
&#xD;
          -  18 years of age and older&#xD;
&#xD;
          -  Non-childbearing potential female subjects is defined as post-menopausal state:&#xD;
             absence of menses for 12 months prior to drug administration or hysterectomy with&#xD;
             bilateral oophorectomy, or tubal ligation at least 6 months prior to drug&#xD;
             administration&#xD;
&#xD;
          -  Capable of consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant illnesses within 4 weeks of the administration of study&#xD;
             medication&#xD;
&#xD;
          -  Clinically significant surgery within 4 weeks prior to the administration of the study&#xD;
             medication&#xD;
&#xD;
          -  Any clinically significant abnormality found during medical screening&#xD;
&#xD;
          -  Any reason which, in the opinion of the medical subinvestigator, would prevent the&#xD;
             subject from participating in the study&#xD;
&#xD;
          -  Abnormal laboratory tests judged clinically significant&#xD;
&#xD;
          -  Positive testing for hepatitis B, hepatitis C or HIV at screening&#xD;
&#xD;
          -  ECG abnormalities or vital sign abnormalities at screening&#xD;
&#xD;
          -  BMI greater than or equal to 30.0 kg/m2&#xD;
&#xD;
          -  History of significant alcohol abuse within six months of the screening visit or any&#xD;
             indication of the regular use of more than fourteen units of alcohol per week&#xD;
&#xD;
          -  History of drug abuse or use of illegal drugs: soft drugs (marijuana) within 3 months&#xD;
             prior to the screening visit or hard drugs (cocaine, PCP, crack) within 1 year prior&#xD;
             to the screening visit or positive urine drug screen at screening&#xD;
&#xD;
          -  History of allergic reactions to heparin, doxycycline, or other related drugs&#xD;
&#xD;
          -  Use of any drugs known to induce or inhibit hepatic drug metabolism within 30 days&#xD;
             prior to administration of the study medication&#xD;
&#xD;
          -  Use of an investigational drug or participation in an investigational study, within 30&#xD;
             days prior to administration of the study medication.&#xD;
&#xD;
          -  Clinically significant history or presence of any clinically significant&#xD;
             gastrointestinal pathology, unresolved gastrointestinal symptoms, liver or kidney&#xD;
             disease, or other conditions known to interfere with the absorption, distribution,&#xD;
             metabolism, or excretion of the drug&#xD;
&#xD;
          -  Any clinically significant history or presence of clinically significant neurological,&#xD;
             endocrinal, cardiovascular, pulmonary, hematologic, immunologic, psychiatric, or&#xD;
             metabolic disease&#xD;
&#xD;
          -  Use of prescription medication within 14 days prior to administration of study&#xD;
             medication or over-the-counter products within 7 days prior to administration of study&#xD;
             medication, except for topical products without systemic absorption&#xD;
&#xD;
          -  Difficulty to swallow study medication&#xD;
&#xD;
          -  Smoking more than 25 cigarettes per day Any food allergy, intolerance, restriction or&#xD;
             special diet that, in the opinion of the Medical Sub-Investigator, could&#xD;
             contraindicate the subject's participation in the study A depot injection or an&#xD;
             implant of any drug within 3 months prior to administration of study medication&#xD;
&#xD;
          -  Donation of plasma (500 mL) within 7 days prior to drug administration. Donation or&#xD;
             loss of whole blood (excluding the volume of blood that will be drawn during the&#xD;
             screening procedures of this study)prior to the administration of the study medication&#xD;
             (50 mL to 300 mL of whole blood within 30 days, 301 mL to 500 mL of whole blood within&#xD;
             45 days, or more than 500 mL of whole blood within 56 days prior to drug&#xD;
             administration)&#xD;
&#xD;
          -  History or presence of clinically significant gastro-oesophageal reflux, stomach&#xD;
             ulcers, or indigestions&#xD;
&#xD;
          -  History or presence of clinically significant severe renal or hepatic dysfunction&#xD;
&#xD;
          -  History or presence of clinically significant myasthenia gravis&#xD;
&#xD;
          -  Breast-feeding subject&#xD;
&#xD;
          -  Positive urine pregnancy screen&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benoit Girard, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anapharm</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anapharm</name>
      <address>
        <city>Sainte-Foy</city>
        <state>Quebec</state>
        <zip>G1V 2K8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <study_first_submitted>April 1, 2008</study_first_submitted>
  <study_first_submitted_qc>April 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2008</study_first_posted>
  <last_update_submitted>April 1, 2008</last_update_submitted>
  <last_update_submitted_qc>April 1, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2008</last_update_posted>
  <responsible_party>
    <name_title>Alfred Elvin/Director of Biopharmaceutics</name_title>
    <organization>Par Pharmaceutical, Inc.</organization>
  </responsible_party>
  <keyword>bioequivalence</keyword>
  <keyword>doxycycline monohydrate</keyword>
  <keyword>fasting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

